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ABSTRACT  Stereotactic body radiotherapy (SBRT) for small lung tumors has been reported 
to achieve very promising treatment outcomes. At our institution, 25 lesions in 22 patients 
were treated with this technique over a 5-year period. All patients had medically inoperable 
lung tumors ≤ 5 cm in size or had refused surgery. In cases of metastatic tumors, the number 
of lesions did not exceed 2. Radiotherapy was performed under strict patient immobilization 
with an exclusive fixation device. Tumor volumes were determined by 4-dimensional computed 
tomography, under free breathing, and the position of the radiation field was verified by linac 
graphy at each treatment. A total of 48 Gy in 4 fractions was delivered by 6–10 non-opposed 
beams. The 3-year local control rate was 92% for primary lung cancer and 75% for metastatic 
lung cancer. The 3-year overall survival rate for primary and metastatic lung cancers were 
65% and 56%, respectively. Metastasis from colorectal cancer was associated with poor local 
control. Severe adverse effects were not observed. The SBRT method used provided safe and 
effective treatment.
 (Accepted on September 21, 2012)
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INTRODUCTION
   Stereotactic body radiotherapy (SBRT) is a 
treatment method that can be carried out with 
strict immobilization of the patient and accurate 
geometrical targeting using an image-guided 
radiotherapy system. Although amazing treatment 
results have been reported for small lung tumors, 
the detailed procedure of SBRT varies according 
to the institution at which it is performed. We 
introduced the use of SBRT for lung tumors in 2007 
and, herein, present the procedure used for SBRT 
and confirm the treatment results obtained with the 
method at our institution.
MATERIALS AND METHODS
   Since July 2007, 28 lung lesions in 25 patients 
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have been treated by SBRT at our institution; 3 
patients who had follow-up periods of <6 months 
were excluded from this analysis. Therefore, 25 
lesions in 22 patients were included in the present 
study. Two of the patients had 2 metastatic lesions 
each, and 1 patient received a second SBRT 
treatment for asynchronous primary lung cancer. 
   The criteria used to define patients eligible for 
SBRT included Stage I primary lung cancer or 
metastatic lung cancer with up to 2 lesions; a major 
axis of the lesion of ≤ 5 cm; absence of active 
lesions outside of the lung; a high suspicion of 
malignancy based on diagnostic imaging or clinical 
course when not proven by pathologic findings; 
medically inoperable lesions or patient refusal for 
surgery; a forced expiratory volume in 1 sec of ≥
700 ml; absence of active interstitial pneumonitis 
and pulmonary fibrosis; and willingness to provide 
written informed consent.
   The radiotherapy equipment consisted of a 
computed tomography (CT) scanner (Asteion 4, 
Toshiba, Tokyo, Japan), a 3-dimensional radiation 
treatment planning (RTP) system (XiO, Elekta, 
Stockholm, Sweden), and a linac machine (PRIMUS 
MD2, Siemens, Munich, Germany). Radiotherapy 
was planned according to CT images. Before 
acquiring CT images, the patient was strictly 
immobilized with an exclusive device (ESFORM 
Fig. 1　Patient set-up with the exclusive immobilization 
device.
Body Support System®, Engineering System, 
Nagano, Japan) (Fig. 1), under oxygen inhalation, 
to minimize the patient’s respiratory movement. 
Two series of CT scans during free breathing 
were obtained. The first series included the entire 
lung and adjacent parts of the body. In the second 
series, thin slice images around the lesion were 
acquired using 4-dimensional CT. During the 12-
sec scan, 12 consecutive images were acquired at 
each slice. These images, including those taken 
during the inspiratory and expiratory phases, were 
digitally added and reproduced into a new series (1 
image per slice). This digitally reproduced series 
was called, “dynamic CT”. The first and second 
series were integrated on the RTP system using a 
CT-CT fusion technique. The tumor volume was 
contoured on the “dynamic CT” series to yield an 
internal target volume (ITV), and a planning target 
volume (PTV) was created by adding a 5-mm setup 
margin to the ITV. Organs at risk were contoured 
on the first CT series. Six to ten radiation beams 
were arranged in a non-opposing fashion to deliver 
a total dose of 48 Gy in 4 fractions at the center 
of the PTV for peripheral lesions with aperture 
margins of 5–7 mm (Fig. 2). For central lesions, 
when dose constraints for the central organs at risk 
could not be cleared, an altered dose fractionation of 
60 Gy in 10 fractions was applied. Dose constraints 
for the organs at risk are listed in Table 1. Dose 
distributions were calculated using the Clarkson 
algorithm with heterogeneity correction. At the time 
of each treatment, verification films (linac graphy) 
were obtained and the position of the isocenter was 
corrected, if necessary.
   Tumor response was classified as either 
“uncontrolled,” characterized by apparent 
tumor enlargement or regrowth, or “controlled,” 
characterized by a decreased or unchanged tumor 
size or uncertain findings masked by radiation 
fibrosis. Local control and survival from the 
initiation of radiotherapy were calculated using the 
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Fig. 2　An example of beam arrangement and dose distribution.
Table 1. Dose constrains for organs at risk
Lung (Lung – PTV) V40 ≤  100 ml
Mean dose ≤  18 Gy
%V15 ≤  25%
%V20 ≤  20%
Spinal cord (+ 3 mm margin) Maximal dose ≤  25Gy
Pulmonary artery (+ 5 mm margin) V40 ≤  1 ml
V35 ≤  10 ml
Esophagus (+ 5 mm margin) V40 ≤  1 ml
V35 ≤  10 ml
Stomach and intestine (+ 5 mm margin) V36 ≤  10 ml
V30 ≤  100 ml
Bronchus (+ 5 mm margin) V40 ≤  10 ml
PTV; Planning target volume, Vx; Volume of the organ receiving at least X Gy, 
%Vx; percent volume of the organ receiving at least X Gy
Kaplan-Meier method. Statistical analyses were 
performed using JMP version 10 (SAS institute, 
Tokyo, Japan).
   The study was approved by the ethics committee 
of Kawasaki Medical School.
RESULTS
   The patient and tumor characteristics are 
summarized in Table 2. The median age of the 
patients was 74 years (range, 39–92 years), and 
the median follow-up period was 18 months 
(range, 8–59 months). Tumors were classified as 
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Fig. 3　Local control rates after stereotactic body radiotherapy according to tumor origin.
Table 2. Patient characteristics
Number of Patients
　　  　Male
　　  　Female
Age (y), median (range)
16
6
74 (39-92)
Number of lesions
　　  　Primary lung cancer
　　  　Metastatic lung cancer
Histology
　　  　Adenocarcinoma
　　  　Squamous cell carcinoma
　　  　Adenoid cystic carcinoma
　　  　Not proven
Tumor diameter (mm), median (range)
Stage of primary lung cancer
　　  　IA
　　  　IB
Primary site of metastatic lung cancer
　　  　Lung
　　  　Colorectal
　　  　Submandibular gland
　　  　Esophagus
　　  　Unknown primary
14
11
11
8
1
5
20 (3-50)
11
3
6
2
1
1
1
“controlled” in 21 of the 25 lesions. Four patients 
developed local recurrence, with 2 primary lung 
adenocarcinomas recurring 8 and 47 months after 
treatment and 2 metastatic lung carcinomas, derived 
from colorectal cancer, recurring 12 and 22 months 
after treatment. The cumulative control rate is 
shown in Fig. 3. The 3-year local control rates 
for all lesions, primary lung cancer lesions, and 
metastatic lung cancer lesions were 82%, 92%, and 
75%, respectively.
   Of the 14 patients with primary lung cancer 
(1 patient developed primary lung cancer after 
SBRT for metastatic cancer and was counted as 
“overlapping”), 2 died as a result of the disease, 1 
died of heart disease, 3 were alive with persistent 
cancer, and 8 were disease-free at the last follow-
up visit. Of the 9 patients with metastatic lung 
cancer, 1 died of the disease, 1 died of other causes 
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Fig. 4　Overall survival rates after stereotactic body radiotherapy according to tumor origin.
Fig. 5　Cause-speciﬁc survival rates after stereotactic body radiotherapy according to tumor origin.
(unidentified), 4 were alive with persistent cancer, 
1 was salvaged by surgery, and 2 were alive and 
disease-free at the last follow-up. The cumulative 
survival rate is shown in Figs. 4 and 5. The overall 
3-year survival rates were 65% and 56% for primary 
and metastatic cancer, respectively. The cause-
specific 3-year survival rates were 78% and 67% for 
primary and metastatic lung cancers, respectively.
   No severe adverse effects were observed, and none 
of the patients developed symptomatic radiation 
pneumonitis or had worsened dyspnea after SBRT.
DISCUSSION
   Stereotactic body radiotherapy (SBRT) for small 
lung tumors has recently become available, with the 
development of the necessary treatment equipment. 
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This modality achieves a large biological effect by 
applying hypofractionated radiotherapy to a precise 
anatomic location, resulting in very promising 
treatment outcomes. The reported 5-year local 
control and overall survival rates reach up to 92% 
and 72%, respectively, for Stage IA lung cancers 
and up to 73% and 62%, respectively, for Stage 
IB lung cancers1). These results are similar to 
those obtained with surgery, and yet, SBRT can be 
performed safely without a resultant deterioration in 
pulmonary function, even in patients with chronic 
obstructive pulmonary disease2,3). Given these 
results, SBRT has become a primary strategy for 
treating medically inoperable lung cancer and for 
treating lung oligometastasis4). 
   The SBRT results observed at our institution were 
comparable to other reported outcomes, showing 
that our treatment policy and procedures are 
acceptable. Local control of metastatic lung tumors 
was worse than that observed for primary lung 
cancers; this tendency seemed especially apparent 
in cases of metastasis from colorectal cancers, 
which also in agreement with previously published 
reports5,6).
   Technically, 2 important aspects must be taken 
into account for the successful treatment of patients 
with SBRT. The first is the precise immobilization 
of the patient and the second is the control of 
tumor movement resulting from breathing. These 2 
considerations are very important in this modality 
because geometric errors are critical to the highly 
precise irradiation that is required. The procedure 
described here employs a body frame system for 
patient immobilization and 4-dimensional CT with 
oxygen inhalation to minimize and optimize the 
target volume. Although other technical approaches 
to minimize tumor movement, including breath-
holding or respiratory-gated irradiation have been 
reported7), the described method is convenient and 
may be implemented without special devices. These 
attributes make this method one of the most popular 
in Japan8,9).
   The SBRT technique has some deficiencies 
that will need to be addressed in the future. First, 
judging the treatment effect is difficult because of 
radiation-induced fibrosis, which frequently appears 
and remains in the irradiated lung10). Radiation-
induced lung fibrosis often presents as a mass-
like consolidation that mimics residual or recurrent 
tumors. A long follow-up period with no evidence 
of tumor regrowth is the only way to diagnose a 
complete response. For this reason, residual tumor 
shadows without enlargement were defined as 
“controlled.” Second, optimal dose-fractionation 
is not clear, especially in centrally located tumors. 
A biologically effective dose (BED) of 83.2–146 
Gy has been reported to result in superior overall 
survival, compared with higher or lower doses11). 
The 48-Gy radiation dosing in 4 fractions resulted 
in a BED of 106 Gy, which appeared reasonable 
for peripheral tumors. For centrally located tumors, 
however, some literature reports severe toxicity12,13), 
and we should recognize that the safety of SBRT for 
these tumors has not yet been established. Finally, 
despite the high rate of local control, this method 
has limited effect in terms of patient survival. 
Overall survival is reported to correlate with the 
development of distant metastasis14). Although 
future challenges include additional concurrent 
or adjuvant systemic therapy, these combined 
modalities have latent risks of increasing adverse 
effects. Well-controlled prospective studies are 
required to evaluate these risks.
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